Blair William & Co. IL Sells 1,431 Shares of Thermo Fisher Scientific Inc. $TMO

Blair William & Co. IL cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 134,124 shares of the medical research company’s stock after selling 1,431 shares during the quarter. Blair William & Co. IL’s holdings in Thermo Fisher Scientific were worth $65,053,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC boosted its stake in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after buying an additional 988 shares during the period. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Wedbush Securities Inc. boosted its position in shares of Thermo Fisher Scientific by 7.1% during the 2nd quarter. Wedbush Securities Inc. now owns 4,066 shares of the medical research company’s stock valued at $1,649,000 after acquiring an additional 270 shares during the last quarter. Fox Run Management L.L.C. grew its holdings in shares of Thermo Fisher Scientific by 171.7% during the second quarter. Fox Run Management L.L.C. now owns 4,885 shares of the medical research company’s stock worth $1,981,000 after purchasing an additional 3,087 shares in the last quarter. Finally, AE Wealth Management LLC increased its position in shares of Thermo Fisher Scientific by 4.4% in the second quarter. AE Wealth Management LLC now owns 63,647 shares of the medical research company’s stock worth $25,807,000 after purchasing an additional 2,702 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $541.20, for a total value of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. This trade represents a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Down 3.3%

NYSE TMO opened at $501.72 on Friday. The stock’s 50 day moving average is $567.28 and its 200 day moving average is $548.67. The company has a quick ratio of 1.53, a current ratio of 1.89 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $186.38 billion, a PE ratio of 28.28, a P/E/G ratio of 2.89 and a beta of 0.96. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, beating the consensus estimate of $6.45 by $0.12. The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The company’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter last year, the firm posted $6.10 earnings per share. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is presently 9.70%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Friday, January 9th. Stifel Nicolaus lifted their price objective on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a report on Friday, January 9th. KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 target price for the company in a research report on Sunday, December 7th. The Goldman Sachs Group initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, December 9th. They set a “buy” rating and a $685.00 price target on the stock. Finally, HSBC upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Monday, December 1st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $633.68.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.